{"name":"Aptinyx","slug":"aptinyx","ticker":"APTX","exchange":"NASDAQ","domain":"aptinyx.com","description":"Aptinyx is a CNS-focused biopharmaceutical company developing novel therapeutics for the treatment of brain and nervous system disorders. The company's pipeline includes NYX-458 and NYX-2925, both in Phase 2 clinical trials. Aptinyx aims to leverage its proprietary NMDA receptor modulator technology to address significant unmet medical needs in the CNS space.","hq":"Evanston, IL","founded":0,"employees":"","ceo":"Norbert Riedel, Ph.D.","sector":"CNS / Neuroscience","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"$85M","metrics":{"revenue":1000000,"revenueGrowth":0,"grossMargin":0,"rdSpend":42748000,"netIncome":-64849000,"cash":66684000,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2021"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[{"date":"2023-02-23","type":"regulatory","headline":"Aptinyx Announces FDA Clearance of IND for NYX-458","summary":"Aptinyx received FDA clearance to initiate a Phase 2 clinical trial for NYX-458.","drugName":"NYX-458","sentiment":"positive"},{"date":"2022-11-14","type":"earnings","headline":"Aptinyx Reports Third Quarter 2022 Financial Results","summary":"Aptinyx reported its Q3 2022 financial results, including a net loss of $13.4 million.","drugName":"","sentiment":"neutral"},{"date":"2022-08-01","type":"deal","headline":"Aptinyx Announces Collaboration with University of California, San Diego","summary":"Aptinyx partnered with the University of California, San Diego to advance its research in the field of CNS disorders.","drugName":"","sentiment":"positive"}],"realNews":[{"date":"2023-12-21","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: FORM 8-K","headline":"SEC 8-K: FORM 8-K","sentiment":"neutral"},{"date":"2023-12-18","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: FORM 8-K","headline":"SEC 8-K: FORM 8-K","sentiment":"neutral"},{"date":"2023-07-03","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: FORM 8-K","headline":"SEC 8-K: FORM 8-K","sentiment":"neutral"},{"date":"2023-05-18","type":"earnings","source":"SEC EDGAR","summary":"10-Q filed with SEC: 10-Q","headline":"Quarterly Report (10-Q) Filed","sentiment":"neutral"},{"date":"2023-05-11","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: FORM 8-K","headline":"SEC 8-K: FORM 8-K","sentiment":"neutral"},{"date":"2023-05-05","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: FORM 8-K","headline":"SEC 8-K: FORM 8-K","sentiment":"neutral"},{"date":"2023-04-25","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: FORM 8-K","headline":"SEC 8-K: FORM 8-K","sentiment":"neutral"},{"date":"2023-04-18","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: FORM 8-K","headline":"SEC 8-K: FORM 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiiwJBVV95cUxPeUdlZURWaFdLR3Nja19CamVNd3ZpWFZKOTdNUHBxY1NMV2VobGNDSHZoVWtMTlJlTHBHSnVSckdEQVZ5amRhSkgtU3U0VjYyLW1YZGtZeHJNMURHenlaejZTekVYMk45TFZmbXppQjRRei1PbmhPQ2RCWHhUUk42YWRjRm0yeWt4RzVpaHZrNmFXbWhRX1FXMlRkMjlHaXktZ1Y4alhXanh2aEhTQkxFX2lLT1VjVHdHVGpPdmtIOF8zNGZPbzMxa3ZuMm9qMU1LQklqRm0wcWZMcUVCZG5KaFRoWUxlSWdEXzloNmgtOVFmeTduMVB4eTl4SnFNejBPa3pLR0N6NWMtbkU?oc=5","date":"2018-06-25","type":"pipeline","source":"PR Newswire","summary":"Aptinyx Announces Closing of Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares - PR Newswire","headline":"Aptinyx Announces Closing of Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Sh","sentiment":"neutral"}],"patents":[],"drugCount":0,"phaseCounts":{},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":["Biogen","Pfizer","Eli Lilly"],"therapeuticFocus":["CNS disorders","neuroscience"],"financials":{"source":"sec_edgar","revenue":1000000,"revenuePeriod":"2021-12-31","revenueHistory":[{"value":1000000,"period":"2021-12-31"},{"value":1000000,"period":"2021-12-31"},{"value":1564000,"period":"2020-12-31"},{"value":1564000,"period":"2020-12-31"},{"value":3669000,"period":"2019-12-31"}],"grossProfit":null,"grossProfitHistory":[],"rdSpend":42748000,"rdSpendHistory":[],"sgaSpend":null,"operatingIncome":null,"operatingIncomeHistory":[],"netIncome":-64849000,"netIncomeHistory":[],"eps":null,"epsHistory":[],"cash":null,"cashHistory":[],"totalAssets":66684000,"totalLiabilities":null,"totalDebt":null,"equity":null,"operatingCashflow":null,"operatingCashflowHistory":[],"capex":null,"capexHistory":[],"freeCashflow":null,"dividendsPaid":null,"buybacks":null,"employees":null,"segmentRevenue":[],"geographicRevenue":[],"ciks":null,"lastFiledAt":null},"yahoo":null}